- Email: [email protected]
5384122 Herpesvirus particles and vaccine
IV
Patents Alert
a metering chamber having a spring-biased piston mounted therein during the injection of a medicament to an animal. During the injection, fluid is forced out of the metering chamber and through the needle assembly by the spring-biased piston. After the injection, fluid pressure forces the needle assembly out of engagement with the metering chamber and enables the metering chamber to be refilled.
out in conjunction with artificially contacting the mammal's immune system with an antigen for a suitable period of time to stimulate the immune system. In another embodiment, the mammal's immune system is naturally exposed to the antigen prior to the non-specific enhancement of the immune system. In yet another embodiment, the invention is directed at a method for preparing an autologous non-specific leukocyte adjuvant.
5382657 5384122 PEG-INTERFERON
CONJUGATES
Karasiewicz Robert; Nalin Carlo; Rosen Perry Parsippany, N J, UNITED STATES Assigned to Hoffmann-La Roche Inc Substituted PEG-interferon conjugates o f formulae IA and IB where PEG is linked by means of activated linking reagents of formulae IIA, liB, or IIB-I to an amino group in the interferon, and activated linking reagents of formulae IIA, liB, or IIB-1. The conjugates are not readily susceptible to in vivo hydrolytic cleavage, have enhanced in vivo half life, and reduce the immunogenicity of the interferon while maintaining biological activity.
5~3~7
HERPESVIRUS PARTICLES AND VACCINE Cunningham Charles; McLauchlan John; Rixon Frazer J; Szilagyi Jozsef F Kirkintilloch, UNITED KINGDOM A s s i g n e d to Medical Research Council in addition to virions, herpesvirus-infected cells produce n o n - i n f e c t i o u s p a r t i c l e s , t e r m e d L - p a r t i c l e s , which c o n s i s t of tegument surrounded by e n v e l o p e but lack the nucleocapsid. L-particles of a herpesvirus can be prepared substantially free of infectious virions, e.g. by a l l o w i n g an a p p r o p r i a t e temperature-sensitive mutant to replicate at its n o n - p e r m i s s i v e t e m p e r a t u r e , and such L-particles are useful as a component of a vaccine against the herpesvirus. They can also be prepared to contain a foreign protein or peptide, by use of a recombinant herpesvirus.
NON-SPECIFIC IMMUNE SYSTEM ENHANCEMENT Edelson Richard Westport, CT, UNITED STATES Assigned to Therakos inc The present invention pertains to a method for non-specifically enhancing the immune system response of a mammal to an antigen which comprises the steps of (a) withdrawing leukocyte containing material from the mammal, (b) treating the withdrawn leukocytes in a manner to alter the cells, and (c) returning the treated leukocytes to the mammal. In one embodiment, the method for non-specifically enhancing the immune system response of a mammal is carried
5386014 CHEMICALLY MODIFIED HEMOGLOBIN AS AN EFFECTIVE, STABLE, NON-IMMUNOGENIC RED BLOOD CELL SUBSTITUTE Nho Kwang; Zalipsky Shmuel; Davis Frank Highland Park, NJ, UNITED STATES Assigned to Enzon Inc The present invention relates to chemically
Patents Alert
a metering chamber having a spring-biased piston mounted therein during the injection of a medicament to an animal. During the injection, fluid is forced out of the metering chamber and through the needle assembly by the spring-biased piston. After the injection, fluid pressure forces the needle assembly out of engagement with the metering chamber and enables the metering chamber to be refilled.
out in conjunction with artificially contacting the mammal's immune system with an antigen for a suitable period of time to stimulate the immune system. In another embodiment, the mammal's immune system is naturally exposed to the antigen prior to the non-specific enhancement of the immune system. In yet another embodiment, the invention is directed at a method for preparing an autologous non-specific leukocyte adjuvant.
5382657 5384122 PEG-INTERFERON
CONJUGATES
Karasiewicz Robert; Nalin Carlo; Rosen Perry Parsippany, N J, UNITED STATES Assigned to Hoffmann-La Roche Inc Substituted PEG-interferon conjugates o f formulae IA and IB where PEG is linked by means of activated linking reagents of formulae IIA, liB, or IIB-I to an amino group in the interferon, and activated linking reagents of formulae IIA, liB, or IIB-1. The conjugates are not readily susceptible to in vivo hydrolytic cleavage, have enhanced in vivo half life, and reduce the immunogenicity of the interferon while maintaining biological activity.
5~3~7
HERPESVIRUS PARTICLES AND VACCINE Cunningham Charles; McLauchlan John; Rixon Frazer J; Szilagyi Jozsef F Kirkintilloch, UNITED KINGDOM A s s i g n e d to Medical Research Council in addition to virions, herpesvirus-infected cells produce n o n - i n f e c t i o u s p a r t i c l e s , t e r m e d L - p a r t i c l e s , which c o n s i s t of tegument surrounded by e n v e l o p e but lack the nucleocapsid. L-particles of a herpesvirus can be prepared substantially free of infectious virions, e.g. by a l l o w i n g an a p p r o p r i a t e temperature-sensitive mutant to replicate at its n o n - p e r m i s s i v e t e m p e r a t u r e , and such L-particles are useful as a component of a vaccine against the herpesvirus. They can also be prepared to contain a foreign protein or peptide, by use of a recombinant herpesvirus.
NON-SPECIFIC IMMUNE SYSTEM ENHANCEMENT Edelson Richard Westport, CT, UNITED STATES Assigned to Therakos inc The present invention pertains to a method for non-specifically enhancing the immune system response of a mammal to an antigen which comprises the steps of (a) withdrawing leukocyte containing material from the mammal, (b) treating the withdrawn leukocytes in a manner to alter the cells, and (c) returning the treated leukocytes to the mammal. In one embodiment, the method for non-specifically enhancing the immune system response of a mammal is carried
5386014 CHEMICALLY MODIFIED HEMOGLOBIN AS AN EFFECTIVE, STABLE, NON-IMMUNOGENIC RED BLOOD CELL SUBSTITUTE Nho Kwang; Zalipsky Shmuel; Davis Frank Highland Park, NJ, UNITED STATES Assigned to Enzon Inc The present invention relates to chemically